Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
BJU Int. 2021 Oct;128(4):511-518. doi: 10.1111/bju.15334. Epub 2021 Feb 15.
To contribute to the debate regarding the minimum volume of radical cystectomies (RCs) that a hospital should perform by evaluating the association between hospital volume (HV) and postoperative mortality.
Patients who underwent RC for bladder cancer between 1 January 2008 and 31 December 2018 were retrospectively identified from the Netherlands Cancer Registry. To create a calendar-year independent measure, the HV of RCs was calculated per patient by counting the RCs performed in the same hospital in the 12 months preceding surgery. The relationship of HV with 30- and 90-day mortality was assessed by logistic regression with a non-linear spline function for HV as a continuous variable, which was adjusted for age, tumour, node and metastasis (TNM) stage, and neoadjuvant treatment.
The median (interquartile range; range) HV among the 9287 RC-treated patients was 19 (12-27; 1-75). Of all the included patients, 208 (2.2%) and 518 (5.6%) died within 30 and 90 days after RC, respectively. After adjustment for age, TNM stage and neoadjuvant therapy, postoperative mortality slightly increased between an HV of 0 and an HV of 25 RCs and steadily decreased from an HV of 30 onwards. The lowest risks of postoperative mortality were observed for the highest volumes.
This paper, based on high-quality data from a large nationwide population-based cohort, suggests that increasing the RC volume criteria beyond 30 RCs annually could further decrease postoperative mortality. Based on these results, the volume criterion of 20 RCs annually, as recently recommended by the European Association of Urology Guideline Panel, might therefore be reconsidered.
通过评估医院容量(HV)与术后死亡率之间的关系,为有关医院应进行的根治性膀胱切除术(RC)最小量的争论做出贡献。
从荷兰癌症登记处回顾性确定了 2008 年 1 月 1 日至 2018 年 12 月 31 日期间接受 RC 治疗的膀胱癌患者。为了创建一个独立于日历年度的指标,通过在手术前的 12 个月内在同一医院进行的 RC 计数,计算每位患者的 RC 医院容量。通过对 HV 作为连续变量的逻辑回归和非线性样条函数评估 HV 与 30 天和 90 天死亡率之间的关系,该回归调整了年龄、肿瘤、淋巴结和转移(TNM)分期和新辅助治疗。
在 9287 例接受 RC 治疗的患者中,HV 的中位数(四分位距;范围)为 19(12-27;1-75)。在所有纳入的患者中,分别有 208(2.2%)和 518(5.6%)在 RC 后 30 天和 90 天内死亡。在调整年龄、TNM 分期和新辅助治疗后,HV 在 0 到 25 例 RC 之间的术后死亡率略有增加,从 HV 30 开始稳步下降。术后死亡率最低的是最高容量。
基于来自大型全国基于人群队列的高质量数据,本文表明,将 RC 容量标准提高到每年 30 例以上可能会进一步降低术后死亡率。基于这些结果,最近欧洲泌尿外科学会指南小组建议的每年 20 例 RC 的容量标准可能需要重新考虑。